Posted by Michael Wonder on 29 Oct 2025
ICER publishes evidence report on treatments for obesity
29 October 2025 - All three drugs result in substantial weight loss; the therapies are cost effective, but the very large population appropriate for treatment creates important budgetary issues.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of semaglutide (injectable Wegovy, and a yet to be approved oral formulation) (Novo Nordisk) and tirzepatide (Zepbound) (Eli Lilly) for the treatment of obesity.
